AgomAb Therapeutics NV
Research AgomAb Therapeutics NV (AGMB) on Bullrun: market cap USD 447.17M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAGMB
- ExchangeNASDAQ
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 447.17M
- Financial periodQ2 2026
- Net income-EUR 15.49M
Valuation Snapshot
latest market cap is USD 447.17M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 62.55M | -EUR 51.75M | n/a | -1.28 | EUR 86.42M | EUR 1.25M | EUR 130.90M |
| FY2024 | EUR 0 | -EUR 46.27M | -EUR 47.50M | n/a | -1.28 | EUR 171.46M | EUR 1.55M | EUR 188.08M |
| FY2023 | EUR 0 | -EUR 11.39M | -EUR 24.59M | n/a | -0.31 | EUR 122.40M | EUR 1.62M | EUR 151.44M |
| FY2022 | EUR 0 | -EUR 8.14M | -EUR 18.97M | n/a | -0.22 | EUR 27.67M | EUR 62.00K | EUR 66.25M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 447.17M | n/a | n/a | n/a |
About AgomAb Therapeutics NV
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AgomAb Therapeutics NV's market cap?
AgomAb Therapeutics NV's market capitalization is USD 447.17M.
What does AgomAb Therapeutics NV do?
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.